Feb 10, 2025 7:10am EST Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
Feb 05, 2025 7:00am EST Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
Jan 27, 2025 7:00am EST US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
Dec 30, 2024 7:00am EST Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Dec 04, 2024 7:00am EST 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
Nov 11, 2024 7:00am EST Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Nov 04, 2024 7:08am EST Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Oct 18, 2024 9:06am EDT Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Oct 09, 2024 7:00am EDT FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Oct 07, 2024 7:00am EDT Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
